These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 10465542)

  • 1. Design of peptides derived from anti-IgE antibody for allergic treatment.
    Takahashi M; Ohgitani Y; Ueno A; Mihara H
    Bioorg Med Chem Lett; 1999 Aug; 9(15):2185-8. PubMed ID: 10465542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases.
    Chang TW; Wu PC; Hsu CL; Hung AF
    Adv Immunol; 2007; 93():63-119. PubMed ID: 17383539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure based design and characterization of peptides that inhibit IgE binding to its high-affinity receptor.
    McDonnell JM; Beavil AJ; Mackay GA; Jameson BA; Korngold R; Gould HJ; Sutton BJ
    Nat Struct Biol; 1996 May; 3(5):419-26. PubMed ID: 8612071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Omalizumab Biobetter Antibody With Improved Stability and Efficacy for the Treatment of Allergic Diseases.
    Liu P; Pan Z; Gu C; Cao X; Liu X; Zhang J; Xiao Z; Wang X; Guo H; Ju D; Deng SJ
    Front Immunol; 2020; 11():596908. PubMed ID: 33329588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A critical appraisal of omalizumab as a therapeutic option for chronic refractory urticaria/angioedema.
    Lang DM
    Ann Allergy Asthma Immunol; 2014 Apr; 112(4):276-9. PubMed ID: 24589165
    [No Abstract]   [Full Text] [Related]  

  • 6. The application of phage display in allergy research: characterization of IgE, identification of allergens and development of novel therapeutics.
    Edwards MR; Collins AM; Ward RL
    Curr Pharm Biotechnol; 2001 Sep; 2(3):225-40. PubMed ID: 11530877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Progress in the study of allergic disease drugs targeting on IgE/FcepsilonRI signaling pathway].
    Liu ZC; Shi HL; Zhang YF; Zhao LJ
    Yao Xue Xue Bao; 2011 Oct; 46(10):1161-6. PubMed ID: 22242444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-IgE therapy.
    Jardieu P
    Curr Opin Immunol; 1995 Dec; 7(6):779-82. PubMed ID: 8679119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel 2-(substituted phenyl)benzimidazole derivatives with potent activity against IgE, cytokines, and CD23 for the treatment of allergy and asthma.
    Richards ML; Lio SC; Sinha A; Tieu KK; Sircar JC
    J Med Chem; 2004 Dec; 47(26):6451-4. PubMed ID: 15588078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humanization of an antibody directed against IgE.
    Presta LG; Lahr SJ; Shields RL; Porter JP; Gorman CM; Fendly BM; Jardieu PM
    J Immunol; 1993 Sep; 151(5):2623-32. PubMed ID: 8360482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of anti-IgE antibodies.
    Heusser C; Jardieu P
    Curr Opin Immunol; 1997 Dec; 9(6):805-13. PubMed ID: 9492982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in pathology.
    Mauro M; Incorvaia C; Formigoni C; Elia R; Russello M; Pellegrino D
    Panminerva Med; 2012 Dec; 54(4):305-12. PubMed ID: 23123583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The high-affinity IgE receptor: lessons from structural analysis].
    Blank U; Jouvin MH; Guérin-Marchand C; Kinet JP
    Med Sci (Paris); 2003 Jan; 19(1):63-9. PubMed ID: 12836193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
    Navinés-Ferrer A; Serrano-Candelas E; Molina-Molina GJ; Martín M
    J Immunol Res; 2016; 2016():8163803. PubMed ID: 28097159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-IgE monoclonal antibody: a new approach to the treatment of allergic respiratory diseases.
    D'Amato G; Oldani V; Donner CF
    Monaldi Arch Chest Dis; 2003; 59(1):25-9. PubMed ID: 14533279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and characterization of a novel anti-IgE monoclonal antibody.
    Qian W; Zhang X; Li B; Zhang D; Tong Q; Chen L; Zheng L; Kou G; Wang H; Hou S; Guo Y
    Biochem Biophys Res Commun; 2010 May; 395(4):547-52. PubMed ID: 20394728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of small molecules to target the IgE:FcεRI protein-protein interaction in allergies.
    Smith LD; Leatherbarrow RJ; Spivey AC
    Future Med Chem; 2013 Aug; 5(12):1423-35. PubMed ID: 23919552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increase in human basophils IgE-mediated stimulation by omalizumab: a role for membrane FcγRs?
    Chirumbolo S; Olivieri M
    J Allergy Clin Immunol; 2014 May; 133(5):1493-4. PubMed ID: 24642141
    [No Abstract]   [Full Text] [Related]  

  • 19. Omalizumab in children.
    Licari A; Marseglia A; Caimmi S; Castagnoli R; Foiadelli T; Barberi S; Marseglia GL
    Paediatr Drugs; 2014 Dec; 16(6):491-502. PubMed ID: 25404353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure/function studies on IgE as a basis for the development of rational IgE antagonists.
    Helm BA; Sayers I; Padlan EA; McKendrick JE; Spivey AC
    Allergy; 1998; 53(45 Suppl):77-82. PubMed ID: 9788713
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.